Vbx-016 has entered preclinical development.
VAXON Biotech’s third drug product, Vbx-016, is a polypeptide composed of four optimized cryptic peptides derived from four different universal tumor antigens (CEA, MAGE, TERT and HER-2/neu) presented in patients expressing HLA-B7 (20-25% of humans). With this product VAXON Biotech will significantly increase the proportion of patients that will benefit from its proprietary innovative cancer therapy.
Vbx-016 has completed the toxicity preclinical development. Its pharmaceutical development is ongoing. Vbx-016 will be ready to enter clinic in 2017.